USPTO serial 97789361
RP2
Reviewed by CopyMark Law Group
Status 601
- Filing date
- Status date
- Registration date
- —
- Examiner
- —
- Law office
- NEW APPLICATION PROCESSING
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with RP2?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Abingdon, Oxfordshire, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Melanie Howard
MELANIE HOWARD LOEB & LOEB LLP10100 SANTA MONICA BOULEVARD, SUITE 2200LOS ANGELES, CA 90067UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations; viruses; viruses for the treatment of disease; viruses for the treatment of cancer; viruses for inducing immune response; pharmaceuticals; pharmaceuticals for the treatment of cancer; pharmaceuticals for inducing immune response; vaccines; immunotherapy products; gene therapy products; Biological preparations in the nature of viruses for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; biological preparations in the nature of viruses for the treatment of cancer; biological preparations in the nature of viruses for inducing immune response; pharmaceuticals, namely, pharmaceutical preparations and pharmaceutical substances for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals, namely, anti-infectives for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceutical preparations for inducing immune response; vaccines; immunotherapy products, namely, pharmaceutical products for the prevention and treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders | ACTIVE | — |
| 042 | Pharmaceutical drug research and development services; research and development of vaccines and medicines; information, advisory and consultancy services relating to the aforesaid | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 18, 2023 | MAB1 | ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT | — |
| Oct 18, 2023 | MAB1 | ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT | — |
| Oct 18, 2023 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Oct 17, 2023 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Mar 1, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 14, 2023 | NWAP | NEW APPLICATION ENTERED | — |